Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroblastoma × Tissue Banks × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Thoracic Diseases 1 Skin Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Peritoneal Diseases 1 Paraproteinemias 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Diseases 1 Neuroblastoma 1 Nervous System Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Monoclonal Gammopathy of Undetermined Significance 1 Lung Neoplasms 1 Leiomyosarcoma 1 Immunoglobulin Light-chain Amyloidosis 1 Hepatoblastoma 1 HER2 Positive Advanced Gastric Cancer 1 Fallopian Tube Neoplasms 1 Fallopian Tube Diseases 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

Cyclophosphamide 47 Etoposide 27 Irinotecan 25 Temozolomide 24 Melphalan 24 3-Iodobenzylguanidine 22 Topotecan 20 Filgrastim 20 Isotretinoin 19 Carboplatin 18 Granulocyte Colony-Stimulating Factor 16 sargramostim 15 fludarabine 15 Granulocyte-Macrophage Colony-Stimulating Factor 15 humanized 3F8 anti-GD2 monoclonal antibody 14 dinutuximab 13 Peripheral Blood Stem Cell Transplantation 13 Doxorubicin 13 Cisplatin 13 Radiotherapy 12 Interleukin-2 12 Busulfan 12 naxitamab 11 Vincristine 11 fludarabine phosphate 10 aldesleukin 9 Thiotepa 9 Eflornithine 8 Vorinostat 7 Stem Cell Transplantation 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡